Research Article
Risk Factors for Symptomatic Pericardial Effusions Posthematopoietic Stem Cell Transplant
Table 2
Predisposing risk factors for PEF development.
| | Characteristics | Overall cohort, n = 201 | PEF, n = 15 | value |
| | Preparative regimen | | | RIC | 69 (34%) | 2 (13%) | | | MAC | 132 (66%) | 13 (87%) | 0.08 | | Underlying disease | | | Malignant | 71 (35%) | 5 (33%) | | | Nonmalignant | 130 (65%) | 10 (67%) | 1 | | History of acute GVHD | | | Yes | 92 (46%) | 8 (53%) | | | No | 109 (54%) | 7 (47%) | 1 | | History of TA-TMA | | | Yes | 11 (5%) | 3 (20%) | 0.01 | | No | 190 (95%) | 12 (80%) | |
|
|
RIC, reduced intensity chemotherapy; MAC, myeloablative chemotherapy; GVHD, graft versus host disease; PEF, pericardial effusion; TA-TMA, transplant-associated thrombotic microangiopathy.
|
